St. Jude's Universal Live Attenuated Bacterial Streptococcus Pneumoniae Vaccine provides serotype-independent protection against otitis media, sinusitis, pneumonia, and other invasive pneumococcal disease(s).
Jason Rosch, PhD, Department of Infectious Diseases, discusses St. Jude’s Universal Live Attenuated Streptococcus Pneumonia Bacteria Vaccine and how it protects against pneumonia, acute sinusitis, and otitis media. It consists of a genetically modified bacteria that is unable to cause tissue damage or massive inflammation, does not translocate to the blood stream and is rapidly cleared from the body. Another advantage over currently approved vaccines is its ability to recognize bacteria independent of different serotypes, whereas approved vaccines only cover 13 of the over 100 serotypes. Our vaccine generates antibodies against both the bacteria’s polysaccharide capsule and the bacteria’s serotypes, or protein targets.
Acute otitis media, or middle ear infection remains one of the most common infectious diseases worldwide. It is the most common infection for which antibiotics are prescribed in the US despite widespread vaccination. Pneumonia is the single largest cause of death in children worldwide, affecting over 1.5 Million each year. In the US there are over 6 Million infections annually. Pneumonia is also the largest killer in the elderly.
We are currently seeking a partner to commercialize this vaccine.
Attenuated Streptococcus Pneumoniae Strain and Vaccine for Protection Against Pneumococcal Disease (SJ-11-0001)
St. Jude Children's Research Hospital, 2013